Publicacións en colaboración con investigadores/as de University of British Columbia (10)

2024

  1. Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473

  2. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial

    Circulation: Cardiovascular Interventions, Vol. 17, Núm. 12, pp. e013743

2023

  1. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 7, pp. 1934-1948

  2. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2732-2747

2022

  1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 5, pp. 1202-1216.e23

2021

  1. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 7, pp. 2680-2688.e7

  2. Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C

    Journal of Clinical Endocrinology and Metabolism, Vol. 106, Núm. 2, pp. E660-E674

  3. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

    Chest

2020

  1. International severe asthma registry (ISAR): Protocol for a global registry

    BMC Medical Research Methodology, Vol. 20, Núm. 1

2019

  1. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

    The Lancet Respiratory Medicine, Vol. 7, Núm. 1, pp. 46-59